Information Provided By: 
Fly News Breaks for June 9, 2015
CNAT
Jun 9, 2015 | 07:21 EDT
Brean Capital noted Conatus' hiring of a new VP of Clinical Development, which the firm does not view as being a share moving event, but added that the company has several upcoming catalysts and if any one comes through it could provide material upside to the shares. The firm views Conatus very favorably, citing its first-in-class liver disease drug candidate, experienced management team and attractive valuation. Brean Capital reiterated its Buy rating and $13 price target on Conatus shares.
News For CNAT From the Last 2 Days
There are no results for your query CNAT
